Comparing SG&A Expenses: Alkermes plc vs Evotec SE Trends and Insights

SG&A Expenses: A Tale of Two Companies

In the ever-evolving pharmaceutical landscape, understanding the financial strategies of key players is crucial. Alkermes plc and Evotec SE, two prominent companies, have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses over the past decade. From 2014 to 2023, Alkermes plc's SG&A expenses surged by approximately 245%, reflecting a strategic expansion and investment in administrative capabilities. In contrast, Evotec SE, while also increasing its SG&A expenses, exhibited a more moderate growth of around 840%, indicating a steady yet cautious approach to scaling operations.

Key Insights

• Alkermes plc: Notable for its aggressive growth, with expenses peaking in 2023.
• Evotec SE: Demonstrates a consistent upward trend, with a significant jump in recent years.
  These insights provide a window into the strategic priorities of these companies, offering valuable lessons for stakeholders and investors alike.